Tarsus Pharmaceuticals (TARS) to Release Quarterly Earnings on Wednesday

Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) is set to announce its earnings results after the market closes on Wednesday, November 13th. Analysts expect the company to announce earnings of ($0.90) per share for the quarter.

Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last announced its earnings results on Thursday, August 8th. The company reported ($0.88) earnings per share for the quarter, beating the consensus estimate of ($0.98) by $0.10. Tarsus Pharmaceuticals had a negative net margin of 180.00% and a negative return on equity of 63.99%. The firm had revenue of $40.81 million during the quarter, compared to the consensus estimate of $31.30 million. During the same quarter in the previous year, the company posted ($1.17) EPS. On average, analysts expect Tarsus Pharmaceuticals to post $-4 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Tarsus Pharmaceuticals Price Performance

TARS stock traded up $2.63 during trading on Friday, hitting $49.42. The stock had a trading volume of 1,037,463 shares, compared to its average volume of 725,116. The company's 50 day moving average price is $35.50 and its two-hundred day moving average price is $31.90. Tarsus Pharmaceuticals has a 1-year low of $15.47 and a 1-year high of $51.59. The stock has a market cap of $1.88 billion, a price-to-earnings ratio of -10.82 and a beta of 1.00. The company has a debt-to-equity ratio of 0.28, a quick ratio of 6.99 and a current ratio of 7.03.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on TARS shares. Oppenheimer reissued an "outperform" rating and issued a $63.00 target price (up previously from $61.00) on shares of Tarsus Pharmaceuticals in a research note on Friday, August 9th. William Blair upgraded Tarsus Pharmaceuticals to a "strong-buy" rating in a report on Friday, August 30th. One investment analyst has rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Tarsus Pharmaceuticals presently has a consensus rating of "Buy" and a consensus target price of $51.60.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.